Society of Toxicologic Pathology Neuropathology Interest Group Article: Neuropathologic Findings in Nonhuman Primates Associated With Administration of Biomolecule-Based Test Articles

Author:

Bangari Dinesh S.1ORCID,Lanigan Lisa G.2,Goulet Felix3ORCID,Siso Silvia4ORCID,Bolon Brad5ORCID

Affiliation:

1. Global Discovery Pathology, Translational In-Vivo Models Platform, Sanofi, Cambridge, Massachusetts, USA

2. Charles River Laboratories, Ashland, Ohio, USA

3. Charles River Laboratories, Senneville, Quebec, Canada

4. Translational Imaging and Pathology, Codiak BioSciences, Cambridge, Massachusetts, USA

5. GEMpath, Inc., Longmont, Colorado, USA

Abstract

The increasing specificity of novel druggable targets coupled with the complexity of emerging therapeutic modalities for treating human diseases has created a growing need for nonhuman primates (NHPs) as models for translational drug discovery and nonclinical safety assessment. In particular, NHPs are critical for investigating potential unexpected/undesired on-target and off-target liabilities associated with administration of candidate biotherapeutics (nucleic acids, proteins, viral gene therapy vectors, etc.) to treat nervous system disorders. Nervous system findings unique to or overrepresented in NHPs administered biomolecule-based (“biologic”) test articles include mononuclear cell infiltration in most neural tissues for all biomolecule classes as well as neuronal necrosis with glial cell proliferation in sensory ganglia for certain viral vectors. Such test article-related findings in NHPs often must be differentiated from procedural effects (e.g., local parenchymal or meningeal reactions associated with an injection site or implanted catheter to administer a test article directly into the central nervous system) or spontaneous background findings (e.g., neuronal autophagy in sensory ganglia).

Publisher

SAGE Publications

Subject

Cell Biology,Toxicology,Molecular Biology,Pathology and Forensic Medicine

Reference98 articles.

1. Burden of Neurological Disorders Across the US From 1990-2017

2. Thorpe KL, Levey AI, Thomas J. The U.S. burden of neurodegenerative disease. Published 2021. Accessed March 4, 2022. https://www.fightchronicdisease.org/resources/us-burden-neurodegenerative-disease.

3. PhRMA (Pharmaceutical Research and Manufacturers of America). Medicines in development for neurodegenerative diseases—2021 report. Published 2021. Accessed March 4, 2022. https://phrma.org/resource-center/Topics/Medicines-in-Development/Medicines-in-Development-for-Neurodegenerative-Diseases-2021-Report.

4. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease

5. Advances of Antisense Oligonucleotide Technology in the Treatment of Hereditary Neurodegenerative Diseases

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3